Targets › SMN2
5 programs from 3 companies in 12 trials: 6 Phase 3, 2 Phase 4, 2 Phase 2, 2 Phase 1; Neurology; next expected readout Nov 2026.
Open in Phaseline: the race on SMN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Risdiplam (RO7034067) SMN2 pre-mRNA positive modulator | SMN2 | Phase 4 | Muscular Atrophy, Spinal; Spinal Muscular Atrophy (SMA) | Nov 2026 |
| Biogen | Nusinersen (BIIB058) SMN2 pre-mRNA positive modulator | SMN2 | Phase 3 | Spinal Muscular Atrophy; Muscular Atrophy, Spinal | Sep 2027 |
| Biogen | Salanersen (BIIB115) SMN2 splicing modulator that increases production of functional SMN protein | SMN2 | Phase 3 | Spinal Muscular Atrophy; Muscular Atrophy, Spinal; Healthy Volunteer | Jun 2028 |
| Novartis | onasemnogene abeparvovec Survival motor neuron protein exogenous gene | SMN2, SMN1 | Phase 3 | Spinal Muscular Atrophy (SMA) | Apr 2031 |
| Novartis | Onasemnogene Abeparvovec Survival motor neuron protein exogenous gene | SMN2, SMN1 | Phase 3 | Spinal Muscular Atrophy Type I | Dec 2035 |
Muscular Atrophy, Spinal (6) Spinal Muscular Atrophy (SMA) (2) Spinal Muscular Atrophy (2) Healthy Volunteer (1) Spinal Muscular Atrophy Type I (1)
other (4), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.